Research Analysts Offer Predictions for MIRM FY2026 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($0.92) per share for the year. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share.

Several other equities analysts have also commented on the company. Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. Robert W. Baird boosted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Finally, JMP Securities boosted their price target on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $60.73.

Mirum Pharmaceuticals Stock Up 1.2%

Mirum Pharmaceuticals stock traded up $0.61 during midday trading on Wednesday, hitting $49.63. 442,111 shares of the company were exchanged, compared to its average volume of 511,171. The company's fifty day moving average price is $43.26 and its 200-day moving average price is $44.87. The company has a market cap of $2.46 billion, a PE ratio of -24.57 and a beta of 0.95. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals has a fifty-two week low of $27.10 and a fifty-two week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.05. The business had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's revenue was up 61.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.54) EPS.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 27,279 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jolanda Howe sold 57,606 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the sale, the senior vice president now owns 4,841 shares of the company's stock, valued at $214,698.35. This trade represents a 92.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 92,764 shares of company stock worth $4,109,161 in the last three months. 14.36% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. CWM LLC increased its holdings in shares of Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after acquiring an additional 428 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after acquiring an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Mirum Pharmaceuticals during the 4th quarter valued at approximately $35,000. Comerica Bank boosted its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in Mirum Pharmaceuticals during the 4th quarter valued at approximately $42,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.